Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 2Polycythemia Vera 2Primary Myelofibrosis 1

Interventions

fludarabine phosphate 16Cyclophosphamide 15Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Busulfan 9Whole-Body Irradiation 8Mycophenolic Acid 8fludarabine 6Methotrexate 6Cyclosporine 6Radiotherapy 5ruxolitinib 4Biopsy 4Antilymphocyte Serum 4Specimen Handling 3Decitabine 3peginterferon alfa-2a 2givinostat hydrochloride 2givinostat 2bomedemstat 2Stem Cell Transplantation 2Prednisone 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Melphalan 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Cytarabine 2Aspirin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Thrombocythemia, Essential × bomedemstat × Clear all
NCT04262141 2026-01-07

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

University of Miami

Phase 2 Active not recruiting
4 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT05223920 2025-09-22

MK-3543-005

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
81 enrolled 13 charts
Myeloid

Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡